AZ submits filing for Symbicort as single inhaler therapy
AstraZeneca has submitted an EU regulatory application for the new asthma treatment concept Symbicort Single inhaler Therapy (SiT) for the management of persistent asthma with a single inhaler, Symbicort Turbuhaler.
AstraZeneca has submitted an EU regulatory application for the new asthma treatment concept Symbicort Single inhaler Therapy (SiT) for the management of persistent asthma with a single inhaler, Symbicort Turbuhaler.
This new treatment concept is a further development of Symbicort adjustable maintenance dosing, and, once approved, will make asthma treatment more effective and simpler for both the physician and the patient, the company says.
'The Symbicort SiT treatment concept will provide one single inhaler for all situations; for baseline therapy, for increasing the dose during worsenings as well as for acute situations. A separate reliever or rescue bronchodilator will no longer be needed,' said Dr Anders Ekblom, vice president and head of the respiratory and inflammation therapy area, AstraZeneca.
The current worldwide market for fixed combination asthma products is estimated to be worth $3.5bn. To date, Symbicort has been launched in 62 markets and approved in more than 80 countries.